← boardnext 2027-05next 2027-09-30
RNTX
GRIN Therapeutics, Inc.distress 10/10 · high distress / dilution risk$0.84+0%today-55% from 52w high
Lead: idiopathic pulmonary fibrosis · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$4M
Runway
0.3 yrs
Shares 1y
+267%
Price & events
-37.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
-2.4%
1W
-13.2%
1M
-54.3%
3M
-38.6%
6M
-45.7%
1Y
-69.4%
2Y
-96.0%
5Y
-96.0%
All
Overview
- Market Cap
- $71.95M
- Volume
- 19.62K
- 52 Week Range
- $0.84 – $1.88
- Total Shares
- 85.54M
- Float Shares
- 66.30M
- Short %
- 1.05%
- % Held by Insiders
- 5.50%
- % Held by Institutions
- 24.62%
- RVOL
- 0.04x
- Beta
- 1.35
Pipeline stages · 2 programs
Radiprodil
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LTI-03
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | Radiprodil | GRIN-related Neurodevelopmental Disorder | — | recruiting |
| 2027-09-30 Estimated 50% readout ~2027-11-14 | Phase 2 | LTI-03orphanfast track | Idiopathic Pulmonary Fibrosis (IPF) | — | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 7
- 2026Guided 40%readoutPhase 2LTI-03 · Initial data from RENEW Phase 2 trial expected in 2026.SEC 8-K
- Q3 2026Guided 70%readoutPhase 2LTI-03 · Initial topline data from Phase 2 RENEW trialSEC 8-K
- late 2025 or early 2026trial initiationsecondaryPhase 2LTI-03 · Resume U.S. enrollment in Phase 2 trial after clinical hold liftedSEC 8-K
- 2025-11-03fda agreementLTI-03 · FDA lifts clinical hold on Phase 2 RENEW trial for LTI-03 in IPFSEC 8-K
- 2025-09-16fda agreementLTI-03 · FDA agreed MCH/H findings not dose-limiting for proposed 24-week protocolSEC 8-K
- 2025-07-08clinical holdLTI-03 · FDA placed clinical hold on LTI-03 due to lack of NOAEL in 26-week rat study; Phase 2 RENEW trial pausedSEC 8-K
- 2025-06-10clinical holdLTI-03 · FDA placed clinical hold on Phase 2 RENEW trial for IPFSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-07-20Maxim GroupBuy
- 2026-06-01HC Wainwright & Co.Buy
- 2026-01-21Brookline CapitalBuy → Hold
- 2025-09-22HC Wainwright & Co.Buy
- 2025-08-19Brookline CapitalBuy → Hold
Competitors — idiopathic pulmonary fibrosis
- ABBVAbbVie Inc.$451.1B · D2
- UTHRUNITED THERAPEUTICS Corp$22.3B · D0
- TRVITrevi Therapeutics, Inc.$2.5B · D1
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- AVLNAvalyn Pharma Inc.$1.3B · D4
- MNKDMANNKIND CORP$1.2B · D0
- CTNMContineum Therapeutics, Inc.$334M · D2
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- TVRDTvardi Therapeutics, Inc.$25M · D4
- GRIGRI Bio, Inc.$3M · D6
Recent news
- 2026-07-22Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
- 2026-07-21Rein Therapeutics Shareholders Approve Governance and Stock Changes - TipRanks
- 2026-07-21Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com Nigeria
- 2026-07-21Rein Therapeutics expands phase 2 IPF trial to Germany - Investing.com
- 2026-07-21Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial - marketscreener.com
- 2026-07-21Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com Canada
- 2026-07-21Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - GlobeNewswire
- 2026-07-21Rein Therapeutics expects initial lung-trial data in 2H 2026 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.